<DOC>
	<DOCNO>NCT00277810</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , efficacy 3 dos lecozotan combination cholinesterase inhibitor patient mild moderate Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , Efficacy Lecozotan SR Outpatients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Diagnosis probable Alzheimer ` disease Current use cholinesterase inhibitor Able give sign date informed consent life appropriate caregiver home community dwell caregiver accompany patient visit visit patient least daily duration study Significant neurological disease AD Diagnosis major depression History stroke heart disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Cholinesterase Inhibitors</keyword>
	<keyword>Outpatients</keyword>
</DOC>